Upload train.csv with huggingface_hub

train.csv

@@ -27,8 +27,7 @@ Influenza  Surveillance and Response System ( GISRS ) and reported to FluNet  wa
 2024. 
 • During the 28 -day period  from 11 December 2023  to 7 January , 53 and 42 countries provided  data at least 
 once on COVID -19"
-". 
-• During the 28 -day period  from 11 December 2023  to 7 January , 53 and 42 countries provided  data at least 
+"at least 
 once on COVID -19 hospitalizations and admissions to an intensive care unit (ICU) , respectively . From the 
 available data, over  173 000 new hospitalizations and over 1900 new ICU admissions were reported  during 
 the 28 -day period .  Amongst  the countries reporting these data consistently over the current and past 
@@ -42,10 +41,9 @@ risk at the global level based on available evidence.  WHO is currently tracking
 five VOIs  – XBB.1.5, XBB.1.16 , EG.5  BA.2.86  and JN.1 ; and five VUMs : DV.7, XBB, XBB.1.9.1, XBB .1.9.2 and 
 XBB.2.3   
 • The Global WHO Coronavirus (COVID -19) Dashboard  has been updated and adapted with a new interface 
-on 22 December 2023 to support WHO and Member States’ work to transition from COVID -"
-"Coronavirus (COVID -19) Dashboard  has been updated and adapted with a new interface 
 on 22 December 2023 to support WHO and Member States’ work to transition from COVID -19 as an 
-emergency to longer -term disease management, as outlined in WHO’s 3 May 2023 COVID -19 2023 -2025 
+emergency to longer -term disease management, as outlined in WHO’s 3 May 2023 COVID -19 2023"
+"3 COVID -19 2023 -2025 
 Updated Strategic Preparedness and Response Plan . The new dashboard will progressively incorporate more 
 components throughout 2024.  The previous link of the Global WHO Coronavirus (COVID -19) Dashboard will 
 still be active and redirect users  to the new one from 22 December onward. Please note that start time of 
@@ -70,11 +68,10 @@ Global overview
  
 Data  as of 7 January  2024 
 Globally, the number of new weekly cases remained stable during the 28 -day period of 11 December 2023 to 7 
-J"
-" as of 7 January  2024 
-Globally, the number of new weekly cases remained stable during the 28 -day period of 11 December 2023 to 7 
 January 2024 as compared to the previous 28 -day period, with over 1.1 million new cases reported (Figure 1, 
 Table 1). The number of new weekly deaths  decreased by 26% as compared to the previous 28 -day period, with 
+8700  new fatalities"
+"
 8700  new fatalities reported. As of 7 January 2024, over 774 million confirmed cases and over 7 million deaths 
 have been reported globally.  According to estimates obtained from viral loads in wastewater surveillance, clinical 
 detection of cases underestimated the real burden 2 to 19 -fold1,2,3 
@@ -88,14 +85,13 @@ COVID -19, including increases in newly reported cases and, more importantly, in
 deaths – the latter of which are considered more reliable indicators given reductions in testing. Global and 
 national data on SARS -CoV-2 PCR percent positivity are available on WHO’s integrated influenza and other 
 respiratory viruses surveillance dashboard . Recent data (epidemiological week one, 1 to 7 January  2024) from 
-sentinel sites show that"
-"integrated influenza and other 
-respiratory viruses surveillance dashboard . Recent data (epidemiological week one, 1 to 7 January  2024) from 
 sentinel sites show that the SARS -CoV-2 PCR percent positivity from reporting countries averages approximately 
 8% (Figure 2).   
 As many countries discontinue COVID -19-specific reporting and integrate it into respiratory disease surveillance, 
 WHO will use all available sources to continue monitoring the COVID -19 epidemiological situation, especially 
 data on morbidity and impact on h ealth systems. COVID -19 remains a major threat, and WHO urges Member 
+States to maintain, not dism"
+"
 States to maintain, not dismantle, their established COVID -19 infrastructure. It is crucial to sustain, inter alia , 
 early warning, surveillance and reporting, variant tracking, early clin ical care provision, administration of vaccine 
 to high -risk groups, improvements in ventilation, and regular communication.  
@@ -113,10 +109,6 @@ continuously updated to retrospectively incorporate changes in reported COVID -1
 countries.  
  
  
-Figure 1. COVID -19 cases and global deaths by 28 -day intervals reported by WHO Region,  as of 7 January 2024 ( A); "
-"ries.  
- 
- 
 Figure 1. COVID -19 cases and global deaths by 28 -day intervals reported by WHO Region,  as of 7 January 2024 ( A); 26 
 June  to 17 January 2024 (B)** 
  
@@ -130,7 +122,8 @@ B 4
  At the regional level, the number of newly reported 28 -day cases decreased across four of the six WHO regions: 
 the African Region ( -63%), the Region of the Americas ( -18%), the Eastern Mediterranean Region ( -13%), and 
 the European Region ( -13%); while case  numbers increased in two WHO regions: the Western Pacific Region 
-(+77%), and the South -East Asia Region (+379%). The number of newly reported 28 -day deaths decreased or 
+(+77%), and the South -East"
+"77%), and the South -East Asia Region (+379%). The number of newly reported 28 -day deaths decreased or 
 remained stable across five regions: the African Region ( -113%), the Eastern Mediterra nean Region ( -53%), the 
 Western Pacific Region ( -45%), the Region of the Americas ( -41%), and the European Region ( -3%); while death 
 numbers increased in the South -East Asia Region (+564%).  
@@ -138,8 +131,6 @@ At the country level, the highest numbers of new 28 -day cases were reported fro
 198 new cases; -30%), Singapore (174 643 new cases; +117%), Italy (163 599 new cases; -18%), Greece (68 590 
 new cases; +81%), and Malaysia (67 206 n ew cases; +164%). The highest numbers of new 28 -day deaths were 
 reported from Italy (1016 new deaths; -21%), the Russian Federation (679 new deaths; +45%), Poland (543 new 
-deaths; +229%), Sweden ("
-"(1016 new deaths; -21%), the Russian Federation (679 new deaths; +45%), Poland (543 new 
 deaths; +229%), Sweden (446 new deaths; -47%), and Greece (322 new deaths; +79%).  
  
 Table 1. Newly reported and cumulative COVID -19 confirmed cases and deaths, by WHO Region, as of 7 January  2024** 
@@ -162,6 +153,9 @@ last 28 days  Countries
 reporting 
 deaths in 
 the last 28 
+"
+"in 
+the last 28 
 days  
 Europe  701 053  
   (63%)  -13%  278 615 
@@ -181,12 +175,6 @@ Pacific  338 056
  (49%)  8/35  
 (23%)  
 America
-s 42 330  
-  (4%)  -18%  193 223 
-732 
-  (25%)  3 86"
-"3%)  
-America
 s 42 330  
   (4%)  -18%  193 223 
 732 
@@ -210,6 +198,8 @@ Africa  3 354
   (0%)  -113%  175 473  
   (3%)  28/50  
  (56%)  4/50  
+ (8%)"
+" 4/50  
  (8%)  
 Eastern 
 Mediter
@@ -229,12 +219,6 @@ Global  1 113 726
 (45%)  51/234 
 (22%)  
  
-*Percent"
-"7 012 984  
-  (100%)  106/234 
-(45%)  51/234 
-(22%)  
- 
 *Percent change in the number of newly confirmed cases/deaths in the past 28 days, compared to 28 days prior. Data from previous weeks are 
 updated continuously with adjustments received from countries.  
 **See Annex 1: Data, table, and figure notes                                                                                                                                                                     
@@ -256,7 +240,8 @@ Source: Influenza and SARS -CoV-2 surveillance data from GISRS  reported to FluN
 **See Annex 1: Data, table, and figure notes  
  
 7 
- Figure 4. Percentage change in confirmed COVID -19 cases  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
+ Figure 4. Percentage change in confirmed COVID -19 cases  over the last 2"
+"-19 cases  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
  
 **Se e Annex 1: Data, table, and figure notes  
  
@@ -268,9 +253,6 @@ Source: Influenza and SARS -CoV-2 surveillance data from GISRS  reported to FluN
 9 
  Figure 6. Percentage change in confirmed COVID -19 deaths  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
  
-**Se e"
-"6. Percentage change in confirmed COVID -19 deaths  over the last 28 days relative to the previous 28 days, as of 7 January  2024** 
- 
 **Se e Annex 1: Data, table, and figure notes  
  
 10 
@@ -288,14 +270,12 @@ and those due to COVID -19 disease.
   
  
 New hospitalizations  
-During the past 28 days, 5 3 (23%) countries reported data to WHO on new hospitalizations at least once (Figure 7). 
+During the past 28 days, 5 3 (23%) countries reported data to WHO on new hospitalizations at least once (Figure 7)."
+"izations at least once (Figure 7). 
 The Region of the Americas had the highest proportion of countries reporting data on new hospitalizations (1 9 
 countries; 3 4%), followed by the European Region (15 countries; 25%), the African Region (12 countries; 24%), the 
 South -East Asia Region (two countries; 20%), and the Western Pacific Region (five countries; 14%). No country in the 
 Eastern Mediterranean Region shared1. The number of countries that consistently reported new hospitalizations 
-for the period was 9"
-"%), and the Western Pacific Region (five countries; 14%). No country in the 
-Eastern Mediterranean Region shared1. The number of countries that consistently reported new hospitalizations 
 for the period was 9% (22  countries) (Table 2).  
  
 Among the 22 countries consistently reporting new hospitalizations, 8 (36%) countries registered an increase of 20% 
@@ -317,16 +297,12 @@ The highest numbers of new hospital admissions were reported from the United Sta
   
 11 
   
-Table 2. Number of new hospitalization admissions reported by WHO regions, 11 December 2023  to 7 January 2024  
+Table 2. Number of new hospitalization admissions"
+"2. Number of new hospitalization admissions reported by WHO regions, 11 December 2023  to 7 January 2024  
 compared to 16 October to 13  November to 10 December 2023  
 Region  Countries reported at least once in 
 the past 28 days  Countries reported consistently in the past and 
 previous 28 days*  
-Number"
-"to 10 December 2023  
-Region  Countries reported at least once in 
-the past 28 days  Countries reported consistently in the past and 
-previous 28 days*  
 Number of 
 countries 
 (percentage)**  Number of new 
@@ -347,25 +323,8 @@ Pacific  5/35 (14%)  14 300  5/35 (14%)  14 300  +88%
 Global  53/234 (2 3%)  173 547  24/234 ( 10%)  167 646 +40% 
  
 *Percent change is calculated for countries reporting consistently both in the past 28 days and the previous 28 days (compari son period).  
-**Number of countries reported / total number of countries in the region (percentage of reporting).  
-*** N/A represents not available  or applicable .  
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
-  
-"
-"percentage of reporting).  
+**Number of countries reported / total number of countries in the region ("
+"reported / total number of countries in the region (percentage of reporting).  
 *** N/A represents not available  or applicable .  
  
  
@@ -408,10 +367,8 @@ Europe  Czechia  2083  2317  -10%
 Europe  Estonia  420  474  -11%  
 Europe  Italy  8845  13857  -36%  
 Europe  Portugal  29 57 -49%  
-South -East Asia  Indonesia  1337  149  797%"
-"13857  -36%  
-Europe  Portugal  29 57 -49%  
-South -East Asia  Indonesia  1337  149  797%  
+South -East Asia  Indonesia  133"
+"East Asia  Indonesia  1337  149  797%  
 South -East Asia  Bangladesh  21 23 -9% 
 Western Pacific  Brunei Darussalam  588  161  265%  
 Western Pacific  Malaysia  9312  4137  125%  
@@ -435,10 +392,8 @@ Americas (10 countries, 14%), the Western Pacific Region (six countries; 17%) ,
 country; 10%). No country in the Eastern Mediterranean Region reported ICU data during the period. The 
 proportion of coun tries that consistently reported new ICU admissions for the period was 8% (1 8 countries). 
 Among the 1 8 countries consistently reporting new ICU admissions, eight ( 44%) countries showed an increase of 
-"
-"new ICU admissions for the period was 8% (1 8 countries). 
-Among the 1 8 countries consistently reporting new ICU admissions, eight ( 44%) countries showed an increase of 
-20% or greater in new ICU admissions during the past 28 days compared to the previous 28 -day period: Indonesia 
+20% or greater in new ICU admissions during the past 28 days compared to the previous 28 -day period: Indones"
+"the previous 28 -day period: Indonesia 
 (164 vs 18; +811%), Malaysia (135 vs 15; +800%), Singapore (77 vs38; +103%), Estonia (18 vs 10; +80%), Ireland  (20 
 vs 13; +54%), Netherlands (120 vs 86; +40%), Greece (120 vs 88; +36%), and Czechia (18 2 vs 146; +25%)  
 The highest numbers of new ICU admissions were reported from Italy (464 vs 492; -6%), Czechia (182 vs 146; 
@@ -460,12 +415,11 @@ new ICU
 admissions  Percent change in 
 new ICU admissions  
 Africa  13/50 (26%)  6 1/50 ( 2%)  0 N/A  
-Americas  10/56 (1 8%)  386 2/56 (16%)  99 -"
-"6%)  6 1/50 ( 2%)  0 N/A  
 Americas  10/56 (1 8%)  386 2/56 (16%)  99 -55%  
 Eastern   
 Mediterranean  0/22 (<1%)  N/A***  0/22 (<1%)  N/A N/A 
-Europe  12/61 (20%)  1097  8/61 (1 3%)  1032  +3%  
+Europe  12/61 (20%)  1097  8/61 (1 3"
+"7  8/61 (1 3%)  1032  +3%  
 South -East  
 Asia  1/10 (10%)  164 1/10 (10%)  164 +811%  
 Western   
@@ -486,19 +440,14 @@ past 28 days  New ICU admissions in
 previous 28 days  % Change in ICU 
 admissions from 
 previous 28 -day period  
-A"
-"U admissions in 
-past 28 days  New ICU admissions in 
-previous 28 days  % Change in ICU 
-admissions from 
-previous 28 -day period  
 Africa   Mauritania  0 0 N/A 
 Americas   Canada  99 221 -55% 
 Americas  Honduras  0 0 N/A 
 Europe   Italy  464 492 -6% 
 Europe   Czechia  182 146 25%  
 Europe   Netherlands  120 86 40%  
-Europe   Greece  120 88 36%  
+Europe   Greece  120 88 36%"
+"120 88 36%  
 Europe   Sweden  101 158 -36%  
 Europe   Ireland  20 13 54%  
 Europe   Estonia  18 10 80%  
@@ -524,8 +473,6 @@ admissions (“zero reporting”) if there are no new hospital or ICU admissions
   
 15 
  Figure 7.  28 -day global COVID -19 new hospitalizations and ICU admissions, from 3 February 2020  to 7 January 
-2024  (A); and  from 1 May  2023 to 7 January "
-"9 new hospitalizations and ICU admissions, from 3 February 2020  to 7 January 
 2024  (A); and  from 1 May  2023 to 7 January 2024  (B) 
    A 
  
@@ -542,7 +489,8 @@ in grey bars are only from countries reporting hospitalizations or ICU admission
  Severity indicators  
  
 The ICU -to-hospitalization ratio and death -to-hospitalization ratio have been key indicators for understanding 
-COVID -19 severity throughout the pandemic. The ICU -to-hospitalization ratio is used to assess the proportion of 
+COVID -19 severity throughout the pandemic. The ICU -to-hospitalization ratio is used"
+"U -to-hospitalization ratio is used to assess the proportion of 
 patients requiring ICU admission in relation to the total number of hospitalizations. The death -to-hospitalization ratio 
 is used to assess the proportion of death s in relation to hospitalized patients.  
  
@@ -557,10 +505,6 @@ Overall, the ICU -to-hospitalization ratio has been decreasing since the peak in
 dropping below 0.15 since the beginning of 2022, and around 0.05 since the start of 2023  (Figure 8) . The trend has 
 been stable  in recent wee ks. This suggests that a decreasing proportion of new hospitalizations require intensive 
 care.  
-"
-"2023  (Figure 8) . The trend has 
-been stable  in recent wee ks. This suggests that a decreasing proportion of new hospitalizations require intensive 
-care.  
  
 Similarly, the death -to-hospitalization ratio has been showing a general decline since July 2021. Since January 2023, 
 it has remained under 0.15 , varying  between 0.06 to 0.14. This is an encouraging trend indicating a lower mortality 
@@ -569,7 +513,8 @@ risk among hospitalized individuals.
 Please n ote that the causes for these decreases cannot be directly interpreted from these data, but likely include a 
 combination of increases in infection -derived or vaccine -derived immunity, improvements in early diagnosis and 
 clinical care, reduced strain on hea lth systems, and other factors. It is not possible to infer a decreased intrinsic 
-virulence amongst newer SARS -CoV-2 variants from these data.  
+virulence amongst newer SARS -CoV-2 variants"
+"newer SARS -CoV-2 variants from these data.  
  
  
  
@@ -609,12 +554,6 @@ reported both new hospitalizations and new ICU admissions. The d eath ratio figu
 and new deaths.  
 Source : WHO COVID -19 Detailed Surveillance Dashboard  
  
-18 
- SARS -CoV-2 variants of"
-"that reported both new hospitalization 
-and new deaths.  
-Source : WHO COVID -19 Detailed Surveillance Dashboard  
- 
 18 
  SARS -CoV-2 variants of interest  and variants under monitoring  
  
@@ -626,6 +565,8 @@ collection dates, so the number of submissions in a given time period may change
  
 WHO is currently tracking several SARS -CoV-2 variants, including:  
 •  Five variants of interest (VOIs): XBB.1.5, XBB.1.16, EG.5, BA.2.86 and JN.1  
+•  Five variants under monitoring (V"
+" 
 •  Five variants under monitoring (VUMs): DV.7, XBB, XBB.1.9.1, XBB.1.9.2 and XBB.2.3  
  
 Table 6 shows the number of countries reporting VOIs and VUMs, and their prevalence from epidemiological week 
@@ -634,8 +575,6 @@ exhibiting increasing trends are highlighted i n yellow, those that have remaine
 those with decreasing trends are highlighted in green.  
  
 Globally, JN.1 is currently the dominant circulating  VOI (reported by 71 countries), accounting for 65.5% of sequences 
-in week 52 compared to 24.8% in week 48 (Figure"
-"dominant circulating  VOI (reported by 71 countries), accounting for 65.5% of sequences 
 in week 52 compared to 24.8% in week 48 (Figure 10, Table 6). Its parent lineage, BA.2.86, is stable and accounted 
 for 7.8% of sequences in week 52 compared to 7.0% in week 48 (Figure 10, Table 6 ). The initial risk evaluation for 
 JN.1  was published on 19 December 2023, with an overall evaluation of low public health risk at the global level 
@@ -644,7 +583,8 @@ based on available evidence.
 The other VOIs, XBB.1.5, XBB.1.16 and EG.5, have decreased in global prevalence during the same period: XBB.1.5 
 accounted for 3.3% of sequences in week 52, a decrease from 8.3% in week 48; XBB.1.6 accounted for 1.5% of 
 sequences in week 52, a decrease from  6.3% in week 48; EG.5 accounted for 16.6% of sequences in week 52, a 
-decrease from 43.6% in week 48 (Figure 10, Table 6).  
+decrease from 43.6% in week 48 (Fig"
+".6% in week 48 (Figure 10, Table 6).  
  
 All VUMs have shown a decreasing trend over the reporting period (Table 6).  
  
@@ -652,8 +592,6 @@ Sufficient sequencing data to calculate variant prevalence at the regional level
 from four WHO regions: the Region of the Americas, the Western Pacific Region, the South -East Asia Region, and the 
 European Region (Table 7). Among the VOIs, JN.1 was the most reported variant and showing an increasing trend in 
 all the four regions. Except for XBB.1.16 that showed a small increase in the Western Pacific Region, the other VOIs 
-and all the VUMs in all four regions observed dec reasing or stable trends.  "
-"regions. Except for XBB.1.16 that showed a small increase in the Western Pacific Region, the other VOIs 
 and all the VUMs in all four regions observed dec reasing or stable trends.  
  
 With declining rates of testing and sequencing globally (Figure 10), it is increasingly challenging to estimate the 
@@ -680,6 +618,9 @@ adequately assessing the variant landscape.
 * Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not includ e 
 XBB.1.5, XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
  
+ "
+".2.3.  
+ 
  
 Table 7. Weekly prevalence of SARS -CoV-2 VOIs and VUMs by WHO regions, week 48 to week 52 of 2023  
  
@@ -687,8 +628,6 @@ Table 7. Weekly prevalence of SARS -CoV-2 VOIs and VUMs by WHO regions, week 48
  
 * Includes descendant lineages, except those individually specified elsewhere in the table. For example, XBB* does not includ e 
 XBB.1.5, XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
-¥ due to the small numbers of sequences submitted"
-"XBB.1.16, EG.5, XBB.1.9.1, XBB.1.9.2, and XBB.2.3.  
 ¥ due to the small numbers of sequences submitted in these regions, it has not been possible to determine trends for the VOIs  and 
 VUMs in these regions; this is also represented by the shaded cells in the table .   
  
@@ -733,22 +672,14 @@ November  to 3 December  2023
  
    
 Figure 10. Panel A  shows the number, and Panel B  the percentage, of all circulating variants since July to December 2023. The variants 
-shown here include descendent lineages, except for the descendent lineage(s) listed here. The Unassigned category includes lineages 
+shown here include descendent lineages, except for the descendent lineage(s)"
+"except for the descendent lineage(s) listed here. The Unassigned category includes lineages 
 pending for a PANGO lineage name designation, whereas the Other category includes lineages that are assigned but not listed here. 
 Source: SARS -CoV-2 sequence data and metadata from GISAID, from 3 July to 31 December 2023.  
  
  
  
  
-A 
-B  
-22 
- Additional"
-"V-2 sequence data and metadata from GISAID, from 3 July to 31 December 2023.  
- 
- 
- 
- 
 A 
 B  
 22 
@@ -768,9 +699,8 @@ Data for 11 December  2023  to 7 January 2024
 African  Region 
 The African Region reported over 3354 new cases, a 63% decrease as compared to the previous 28 -day period. Five (10%) of the 50 countries for which data are 
 available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Mauritania ( 30 vs six new cases; +400%), Senegal 
-(17 vs six new cases ; +183%), Mali (two vs one new case; +100%), Burundi (78 vs 51 new cases; +53%), and Angola (417 vs 316 new cases; +32%). The  highest 
-numbers of new cases were reported from Mauritius (3228 new cases; 253.8 new cases per 100 000; -57%"
-"; +32%). The  highest 
+(17 vs six new cases ; +183%), Mali (two vs one new case; +100%), Burundi (78 vs 51 new cases; +53%), and Angola ("
+"; +53%), and Angola (417 vs 316 new cases; +32%). The  highest 
 numbers of new cases were reported from Mauritius (3228 new cases; 253.8 new cases per 100 000; -57%), Angola (417 new cas es; 1.3 new cases per 100 000; 
 +32%), and Burundi (78 new cases; <1 new case per 100 000; +53%).  
 The number of new 28 -day deaths in the Region decreased by 113% as compared to the previous 28 -day period, with no new deaths reported. The highest numbers 
@@ -784,8 +714,8 @@ The Region of the Americas reported over 42 000 new cases, an 18% decrease as co
 which data are available reported increases in new cases of 20% or greater, with the highest proportio nal increases observed in Panama (822 vs 180 new cases; 
 +357%), Barbados (33 vs 14 new cases; +136%), Plurinational State of Bolivia  (1563 vs 670 new cases; +133%), Guyana (six vs three new cases; +100%), Colombia 
 (1 680 vs 1 266 new cases; +33%), Paraguay (92 vs 73 new cases; +26%), and Jamaica (32 vs 26 new cases; +23%). The highest numbers of new cases were reported 
-from Canada (18 947 new cases; 50.2 new cases per "
-"), and Jamaica (32 vs 26 new cases; +23%). The highest numbers of new cases were reported 
+from"
+"highest numbers of new cases were reported 
 from Canada (18 947 new cases; 50.2 new cases per 100 000; -18%), Chile (9693 new cases; 50.7 new cases per 100 000; -25%), and Peru (4657 new cases; 14.1 
 new cases per 100 000; -38%).  
 The number of new 28 -day deaths in the Region decreased by 41% as compared to the previous 28 -day period, with 3869 new deaths reported. The highest 
@@ -801,9 +731,9 @@ Updates from the  Region of the Americas
 The Eastern Mediterranean Region reported over 2464 new cases, a 13% decrease as compared to the previous 28 -day period. One (5%) of the 22 countries for 
 which data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Kuwait (102 vs 39 new cases; 
 +162%). The highest numbers of new cases were reported from Afghanistan (1256 new cas es; 3.2 new cases per 100 000; +14%), the Islamic Republic of Iran (663 
-new cases; <1 new case per 100 000; -48%), and Morocco (443 new cases; 1.2 new cases per"
-"ic Republic of Iran (663 
 new cases; <1 new case per 100 000; -48%), and Morocco (443 new cases; 1.2 new cases per 100 000; +6%).  
+The number of new 2"
+"6%).  
 The number of new 28 -day deaths in the Region decreased by 53% as compared to the previous 28 -day period, with 37 new deaths reported. The highest numbers 
 of new deaths were reported from the Islamic Republic of Iran (27 new deaths; <1 new death per 100 00 0; -63%), Afghanistan (8 new deaths; <1 new death per 
 100 000; +60%), and Morocco (2 new deaths; <1 new death per 100 000; +100%).  
@@ -818,9 +748,9 @@ Updates  from  the Eastern  Mediterranean  Region
 The European Region reported over 701 000 new cases, a 13% decrease as compared to the previous 28 -day period. 10 (16%) of the 62 countries for which data 
 are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Malta (310 vs 75 new cases; +313%), Republic 
 of Moldova (2 951 vs 1 485 new cases; +99%), Ireland (3 433 vs 1 856 new cases; +85%), Greece (68 590 vs 37 925 new cases; +81%), the United Kingdom (37 787 vs 
-22 791 new cases; +66%), Romania (7 380 vs 4 916 new cases; +50%), Portugal (4 451 vs 3 103 new cases; +43%), Belgium (10 653 vs 8 623 new cases"
-"16 new cases; +50%), Portugal (4 451 vs 3 103 new cases; +43%), Belgium (10 653 vs 8 623 new cases; +24%), 
-Luxembourg (2 054 vs 1 696 new cases; +21%), and Netherlands (5 330 vs 4 442 new cases; +20%). The highest numbers of new cases were reported from the 
+22 791 new cases; +66%), Romania (7 380 vs 4 916 new cases; +50%), Portugal (4 451 vs 3 103 new cases; +43%), Belgium (10 653 vs 8 623 new cases; +24%), 
+Luxembourg (2 054 vs 1 696 new cases; +21%), and Netherlands (5 330 vs 4 442 new cases; +20%). The highest numbers of new"
+"; +20%). The highest numbers of new cases were reported from the 
 Russian Federation (235 198 new cases; 161.2 new cases per 100 000; -30%), Italy (163 599 new cases; 274.3 new cases per 100 000; -18%), and Greece (68 590 
 new cases; 639.9 new c ases per 100 000; +81%).  
 The number of new 28 -day deaths in the Region decreased by 3% as compared to the previous 28 -day period, with 4194 new deaths reported. The highest numbers 
@@ -835,10 +765,10 @@ Updates  from  the European  Region
 25 
  South -East  Asia  Region  
 The South -East Asia Region reported over 26 000 new cases, a 379% increase as compared to the previous 28 -day period. Five (45%) of the 11 countries for which 
-data are available reported increases in new cases of 20% or greater, with the highest proportion al increases observed in India (15 07"
-"-day period. Five (45%) of the 11 countries for which 
 data are available reported increases in new cases of 20% or greater, with the highest proportion al increases observed in India (15 079 vs 1 599 new cases; +843%), 
 Myanmar (110 vs 20 new cases; +450%), Indonesia (8 610 vs 1 727 new cases; +399%), Bangladesh (276 vs 141 new cases; +96%), and Sri Lanka (67 vs 42 new 
+cases; +"
+"vs 42 new 
 cases; +60%). The highest numbers of new cases were reported from India (15 079 new cases; 1.1 new cases per 100 000; +843%),  Indonesia (8610 new cases; 3.1 
 new cas es per 100 000; +399%), and Thailand (2327 new cases; 3.3 new cases per 100 000; +17%).  
 The number of new 28 -day deaths in the Region increased by 564% as compared to the previous 28 -day period, with 186 new deaths reported. The highest 
@@ -852,17 +782,14 @@ Updates from the South -East Asia Region
 26 
  Western  Pacific  Region  
 The Western Pacific Region reported over 338 000 new cases, a 77% increase as compared to the previous 28 -day period. Ten (29%) of the 35 countries for which 
-data are available reported increases in new cases of "
-"000 new cases, a 77% increase as compared to the previous 28 -day period. Ten (29%) of the 35 countries for which 
 data are available reported increases in new cases of 20% or greater, with the highest proportional increases observed in Niu e (98 vs six new cases; +1533%), Palau 
 (16 vs two new cases; +700%), Tonga (62 vs 12 new cases ; +417%), Cook Islands (29 vs six new cases; +383%), Cambodia (76 vs 16 new cases; +375%), Brunei 
-Darussalam (16 648 vs 4 207 new cases; +296%), Malaysia (67 206 vs 25 484 new cases; +164%), the Philippines (10 262 vs 4 672 new cases; +120%), Singapore 
+Darussalam (16 648 vs 4 207 new cases; +296%), Malaysia (67"
+"296%), Malaysia (67 206 vs 25 484 new cases; +164%), the Philippines (10 262 vs 4 672 new cases; +120%), Singapore 
 (174 643 vs 80 296 new cases; +117%), and China (2 514 vs 1 674 new cases; +50%). The highest numbers of new cases were repor ted from Singapore (174 643 
 new cases; 2985.2 new cases per 100 000; +117%), Malaysia (67 206 new cases; 207.6 new cases per 100 000; +164%), and Australia (41 965 new cases; 164.6 
 new cases per 100 000; -18%).  
 The number of new 28 -day deaths in the Region decreased by 45% as compared to the previous 28 -day period, with 416 new deaths reported. The highest numbers 
-of new deaths were reported from Australia (185 new deaths; <1 new death per 100 000; -67%), Malaysi a (97 new"
-"s reported. The highest numbers 
 of new deaths were reported from Australia (185 new deaths; <1 new death per 100 000; -67%), Malaysi a (97 new deaths; <1 new death per 100 000; +259%), 
 and New Zealand (54 new deaths; 1.1 new deaths per 100 000; -49%).  
  
@@ -874,6 +801,8 @@ Updates from the Western Pacific Region
 Data presented are based on official laboratory -confirmed COVID -19 cases and deaths reported to WHO by 
 coun try/territories/areas, largely based upon WHO case definitions  and surveillance guidance . While steps are taken to 
 ensure accuracy and reliability, all data are subject to continuous verification and change, and caution must be taken when 
+interpreting these"
+"must be taken when 
 interpreting these data as several factors influence the counts presented, with variable underestimation o f true case and 
 death incidences, and variable delays to reflecting these data at the global level. Case detection, inclusion criteria, testi ng 
 strategies, reporting practices, and data cut -off and lag times differ between countries/territories/areas.  Dif ferences are 
@@ -883,8 +812,6 @@ countries of interest, time period, and purpose of the request/intended usage. P
 see covid19.who.int  for the most up -to-date data.  
 ‘Countries’ may refer to countries, territories, areas or other jurisdictions of similar status. The  designations employed, 
 and the presentation of these materials , do not imply the expression of any opinion whatsoever on the part of WHO 
-concerning the legal status of any country, territory, or area or of its authorities, or concerning the delimitation"
-"presentation of these materials , do not imply the expression of any opinion whatsoever on the part of WHO 
 concerning the legal status of any country, territory, or area or of its authorities, or concerning the delimitation of its 
 frontiers or boundaries. Dotted and dashed lines on maps r epresent approximate border lines for which there may not 
 yet be full agreement. Countries, territories, and areas are arranged under the administering WHO region. The mention 
@@ -916,16 +843,4 @@ proprietary products are distinguished by initial capital letters.
 26 
  Annex 2. SARS -CoV-2 variants assessment and classification  
  
-WHO, in collaboration with national authorities, institutions and researchers, routinely assesses if variants of SARS -
-CoV-2 alter transmission or disease characteristics, or impact the effectiveness of vaccines, therapeutics, diagnostics 
-or public health a nd social measures (PHSM) applied to control disease spread. Potential variants of concern (VOCs), 
-variants of interest (VOIs) or variants under monitoring (VUMs) are regularly assessed based on the risk posed to 
-global public health.  
- 
-The classifications of variants will be revised as needed to reflect the continuous evolution of circulating variants and 
-their changing epidemiology. Criteria for variant classification, and the lists of currently circulating and previously 
-circulating VO Cs, VOIs and VUMs, are available on the WHO Tracking SARS -CoV-2 variants website . National 
-authorities may choose to designate other variants and are strongly encouraged to investigate and report newly 
-emerging variants and their impact.  
- 
-WHO continues to monitor SARS -Co"
+WHO, in collaboration with national authorities, institutions and researchers, routinely assesses if variants of S"